The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
Open accessAbstract
BACKGROUND & AIMS: Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of interleukin 23, in a phase 2 study of patients with UC. METHODS: We performed a trial of the efficacy and safety of mirikizumab in patients with moderate to severely active UC, enrolling patients from 14 countries from January 2016 through September 2017. Patients were randomly assigned to groups given intravenous placebo (N = 63), mirikizumab 50 mg (N = 63) or 200 mg (N = 62) with exposure-based dosing, or mirikizumab 600 mg with fixed dosing (N = 61) at weeks 0, 4, and 8. Of assigned patients, 63% had prior exposure to a biologic agent. Clinical responders (decrease in 9-point Mayo score, including ≥2 points and ≥35% from baseline with either a decrease of rectal bleeding subscore of ≥1 or a rectal bleeding subscore of 0 or 1) at week 12 who had received mirikizumab were randomly assigned to groups that received maintenance treatment with mirikizumab 200 mg subcutaneously every 4 weeks (N = 47) or every 12 weeks (N = 46). The primary endpoint was clinical remission (Mayo subscores of 0 for rectal bleeding, with 1-point decrease from baseline for stool frequency, and 0 or 1 for endoscopy) at week 12. A multiple testing procedure was used that began with the 600-mg dose group, and any nonsignificant comparison result ended the formal statistical testing procedure. RESULTS: At week 12, 15.9% (P = .066), 22.6% (P = .004), and 11.5% (P = .142) of patients in the 50-mg, 200-mg, and 600-mg groups achieved clinical remission, respectively, compared with 4.8% of patients given placebo. The primary endpoint was not significant (comparison to 600 mg, P > .05). Clinical responses occurred in 41.3% (P = .014), 59.7% (P < .001), and 49.2% (P = .001) of patients in the 50-mg, 200-mg, and 600-mg groups, respectively, compared with 20.6% of patients given placebo. At week 52, 46.8% of patients given subcutaneous mirikizumab 200 mg every 4 weeks and 37.0% given subcutaneous mirikizumab 200 mg every 12 weeks were in clinical remission. CONCLUSIONS: In a randomized trial of patients with UC, mirikizumab was effective in inducing a clinical response after 12 weeks. Additional studies are required to determine the optimal dose for induction of remission. Mirikizumab showed durable efficacy throughout the maintenance period. Clinicaltrials.gov, Number NCT02589665.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Self-citationInterleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Lee, J. S., Tato, C. M., Joyce-Shaikh, B., Gulen, M. F., Cayatte, C., Chen, Y., Blumenschein, W. M., Judo, M., Ayanoglu, G., McClanahan, T. K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.003 · Cited by 760
Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30570-6 · Cited by 451
Self-citationTargan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383
Self-citationDifferential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
Maxwell, J. R., Zhang, Y., Brown, W. A., Smith, C. L., Byrne, F. R., Fiorino, M., Stevens, E., Bigler, J., Davis, J. A., Rottman, J. B., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.019 · Cited by 342
Sands, B. E., Chen, J., Feagan, B. G., Penney, M., Rees, W. A., Danese, S., Higgins, P. D. R., Newbold, P., Faggioni, R., Patra, K., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.049 · Cited by 279
Self-citationConverging goals of treatment of inflammatory bowel disease from clinical trials and practice
Levesque, B. G., Sandborn, W. J., Ruel, J., Feagan, B. G., Sands, B. E., & Colombel, J.-F. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.08.003 · Cited by 217
Self-citationIL-12-and IL-23 in health and disease
Croxford, A. L., Kulig, P., & Becher, B. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.017 · Cited by 160
Cited by
Pathophysiology of Inflammatory Bowel Diseases
Chang, J. T. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2002697 · Cited by 1,295
Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Cai, Z., Wang, S., & Li, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.765474 · Cited by 675
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
D’Haens, G., Dubinsky, M., Kobayashi, T., Irving, P. M., Howaldt, S., Pokrotnieks, J., Krueger, K., Laskowski, J., Li, X., Lissoos, T., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2207940 · Cited by 361
Self-citationUlcerative colitis: Recent advances in the understanding of disease pathogenesis
Porter, R. J., Kalla, R., & Ho, G.-T. (2020) · F1000Research · doi:10.12688/f1000research.20805.1 · Cited by 300
Central reading of ulcerative colitis clinical trial videos using neural networks
Gottlieb, K., Requa, J., Karnes, W., Chandra Gudivada, R., Shen, J., Rael, E., Arora, V., Dao, T., Ninh, A., & McGill, J. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.024 · Cited by 136
Metadata
- Authors
- Sandborn, W. J., Ferrante, M., Bhandari, B. R., Berliba, E., Feagan, B. G., Hibi, T., Tuttle, J. L., Klekotka, P., Friedrich, S., Durante, M., Morgan-Cox, M., Laskowski, J., Schmitz, J., & D’Haens, G. R.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 158
- Issue
- 3
- Pages
- 537-549.e10
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2971538989
- Cited by
- 229
- References
- 8
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. https://app.cochat.ai/papers/10.1053/j.gastro.2019.08.043
- The paper
- Sandborn, W. J., Ferrante, M., Bhandari, B. R., Berliba, E., Feagan, B. G., Hibi, T., Tuttle, J. L., Klekotka, P., Friedrich, S., Durante, M., Morgan-Cox, M., Laskowski, J., Schmitz, J., & D’Haens, G. R. (2020). Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.08.043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.